Sakurako Kagitani
Papers
1
Total Citations
3
H-Index
1
About
Dr. Sakurako Kagitani is a clinical oncologist and researcher whose work focuses on advancing therapeutic strategies for metastatic renal cell carcinoma (mRCC), particularly through the integration of immuno-oncology and targeted therapies. Her major contributions center on the use of combination regimens, such as lenvatinib plus pembrolizumab, as a bridge to deferred cytoreductive nephrectomy—a paradigm-shifting approach that prioritizes systemic disease control before surgical intervention. In her most cited paper (2023, 3 citations), she presents a compelling case demonstrating how this sequential strategy can achieve durable responses in patients with advanced RCC, offering a personalized alternative to upfront surgery. While her citation count is modest, her work is notable for its clinical relevance in a rapidly evolving field, highlighting the practical application of emerging drug combinations. Dr. Kagitani’s research underscores the importance of timing and patient selection in mRCC management, and her case report serves as a valuable reference for clinicians navigating complex treatment decisions. Her contributions are particularly impactful for oncologists and researchers exploring the synergy between immunotherapy and tyrosine kinase inhibitors.
Research Focus
Key Achievements
Top Papers
- 1